



Article

# Investigation of Heterogeneity of Lipid Nanoparticles for Nucleic Acid Drug Delivery via Sucrose Gradient Density Centrifugation

Yujia Hong <sup>1</sup>, Guanghui Zi <sup>1</sup> and Baowei Peng <sup>1,2,\*</sup> 

<sup>1</sup> College of Pharmacy, Dali University, No. 2 Hongsheng Road, Dali 671003, China

<sup>2</sup> Yunnan Provincial Key Laboratory of Entomological Biopharmaceutical R&D, College of Pharmacy, Dali University, Xueren Road, Dali 671003, China

\* Correspondence: pengbaowei@dali.edu.cn

## Abstract

Lipid nanoparticles (LNPs) have been widely utilized as carriers for nucleic acid drug delivery; however, their inherent heterogeneity impedes the accurate characterization of physicochemical and biological properties. Conventional analytical methods are inherently limited in resolving such heterogeneity. This study employed sucrose density gradient centrifugation (S-DGC) to separate LNP subpopulations of varying densities. It investigated the effects of lipid formulation parameters—including nitrogen-to-phosphorus (N/P) ratio, lipid composition, polyethylene glycol (PEG) concentration—and microfluidic preparation conditions (flow rate) on LNP heterogeneity and biological functionality. Formulation stability was assessed via freeze–thaw testing. The results demonstrated that S-DGC could effectively separate LNP subpopulations with divergent densities and physicochemical characteristics. Changes in the N/P ratio and lipid composition significantly modulate subphase distribution and properties. When cholesterol (Chol) and distearoylphosphatidylcholine (DSPC) are absent from the formulation, LNPs aggregate in the low-density layer (0–10% sucrose density layer). The concentration of PEGylated lipids serves as a critical regulatory factor. When the concentration increased from 0.5% to 2.5%, the LNP particle size decreased from approximately 202 nm to 118.7 nm. Furthermore, the S-DGC profile indicates that LNP transitions from an aggregated low-density distribution to a uniformly dense subpopulation concentrated within the 0–20% sucrose layer, where transfection efficiency is optimal. In freeze–thaw stability assessment, unprotected LNP exhibited a drastic decline in encapsulation efficiency to 5.3% after three freeze–thaw cycles at  $-80^{\circ}\text{C}$ . The S-DGC diagram revealed aggregation in the 20–30% high-density region. However, adding 5% sucrose maintained encapsulation efficiency above 96%. This study confirms that the S-DGC analytical platform serves as a potent tool for resolving LNP heterogeneity and correlating formulation structure with function. Based on these findings, this study contends that during the early prescription development of LNP-based nucleic acid therapeutics, formulation screening should not be confined to meeting overall particle size and encapsulation rate targets. Instead, S-DGC can be employed to proactively identify and minimize ineffective subpopulations (such as particles distributed in extremely high or low density zones), thereby enhancing product quality uniformity and predictability from the outset of R&D.



Academic Editor: Gerhard Kostner

Received: 6 January 2026

Revised: 27 January 2026

Accepted: 28 January 2026

Published: 27 February 2026

**Copyright:** © 2026 by the authors.

Licensee MDPI, Basel, Switzerland.

This article is an open access article distributed under the terms and

conditions of the [Creative Commons](https://creativecommons.org/licenses/by/4.0/)

[Attribution \(CC BY\)](https://creativecommons.org/licenses/by/4.0/) license.

**Keywords:** lipid nanoparticles; heterogeneity; sucrose gradient density centrifugation (S-DGC); physicochemical properties; freeze–thaw

## 1. Introduction

Lipid nanoparticles (LNPs) represent a class of nanocarriers that combine high biocompatibility with efficient nucleic acid delivery. Their efficacy has been clinically validated by COVID-19 mRNA vaccines, and their application is now expanding to the delivery of various nucleic acids, including DNA, mRNA, and siRNA, for both clinical research and therapeutic use [1,2]. The core function of LNPs is to protect these degradation-prone nucleic acid molecules and facilitate their cellular entry to achieve therapeutic effects. They are currently widely employed in diverse clinical fields such as cancer therapy, gene therapy, chemotherapy, infectious disease management, and others [3,4]. LNPs not only prevent enzymatic degradation of the cargo and extend its circulation time—thereby reducing dosing frequency [5], but also, owing to their excellent biocompatibility and low toxicity, maximize therapeutic efficacy while minimizing damage to healthy tissues [6]. Currently, validated LNP formulations typically consist of four core lipid components: ionizable lipids, phospholipids, cholesterol, and PEG-modified lipids. Each of these components plays an indispensable role in achieving efficient nucleic acid delivery [7,8]. Together, they promote the formation of monodisperse nanoparticles, enhance colloidal stability, enable high encapsulation efficiency of nucleic acid drugs, facilitate cellular uptake, and significantly improve endosomal escape efficiency [9].

The efficacy and safety of LNPs are not determined solely by average physicochemical properties such as size and zeta potential. Variability among different particles in lipid composition, drug loading, and internal structure—collectively referred to as “heterogeneity”—also plays a critical role. Differences in the selection and ratio of lipid components, as well as in production methods, can lead to varying degrees of such heterogeneity. These inter-particle differences in composition, payload, and structure ultimately influence key performance attributes, including encapsulation efficiency, morphology, potency, circulation time, biodistribution, and therapeutic efficacy [10–12]. Existing studies have confirmed the complexity and potential heterogeneity of nucleic acid-loaded LNPs. For instance, one approach employed size-exclusion chromatography (SEC) based on S-1000 separation layers to characterize siRNA-loaded LNPs in terms of size distribution, compositional profile, and in vitro functional activity [13]. However, this technique has notable methodological limitations: it separates subpopulations only by hydrodynamic size and cannot resolve particles that are similar in size but differ in density. As a result, the SEC fails to provide a fine-grained analysis of LNP heterogeneity. Whilst single-particle fluorescence-spectroscopic chromatography (SN-FSHS-CICS) enables high-throughput single-particle analysis, its instrumentation is highly specialized, operationally complex, and incapable of preparing purified subpopulations for downstream bioactivity analysis [14]. To address this technical gap, the present study utilizes S-DGC to systematically investigate how formulation composition and key process parameters regulate the heterogeneity of LNP subpopulations defined by density.

Density gradient centrifugation (DGC) is a well-established technique for the purification of biological samples. Its principle relies on the formation of a stepwise or continuous density gradient within a centrifuge tube. When a sample is layered on top of this gradient and subjected to centrifugation, components migrate to positions where their buoyant density matches that of the surrounding medium. Notably, this separation process is robust and stable, largely unaffected by variations in centrifugal force or extended run times [15]. A critical requirement for the gradient medium is that it must be chemically inert and non-interactive with the particles to be separated. Previous studies have demonstrated the applicability of DGC for resolving density-based heterogeneity in mRNA-loaded LNP formulations [16]. Separately, analytical ultracentrifugation (AUC) has been shown to

effectively fractionate LNPs according to their mRNA loading levels while preserving the structural integrity of both the carrier and the payload [17].

Furthermore, the structural and functional properties of LNPs are critically dependent on formulation parameters. The N/P ratio and the molar proportions of the four core lipid components play essential regulatory roles, while the choice of PEG-lipid directly influences key performance attributes such as particle size distribution, colloidal stability, in vivo biodistribution, and transfection efficiency [12,18–20]. Therefore, this study systematically constructed a multivariate LNP library by varying critical parameters including the N/P ratio, lipid composition and ratios, and mixing flow rates, while also evaluating the formulations' freeze–thaw stability. Subsequently, S-DGC was employed to effectively separate LNP subpopulations, followed by a comprehensive and in-depth characterization of their physicochemical properties and in vitro expression activity. This study has transcended the conventional, holistic characterization paradigm for LNPs. By establishing and systematically applying the heterogeneous multidimensional analysis platform of S-DGC, it has achieved the visualization, separation, and quantitative evaluation of “functional subpopulations” within LNP populations. This provides a critical analytical tool for realizing the principle of “quality by design” in LNPs.

## 2. Results

### 2.1. Effects of Different N/P Ratios on LNPs


Using microfluidic technology, LNPs of the standard formulation were prepared at a flow rate of 12 mL/min, with the N/P ratio set at three variable levels: 2, 4, and 6. The prepared LNPs were subsequently separated and purified by S-DGC to systematically investigate the effect of different N/P ratios on their physicochemical properties and transfection efficiency. As shown in Table 1, the particle size of LNP exhibits a significant decreasing trend with increasing N/P ratio. Specifically, the particle size at N/P = 2 (approximately 140 nm) is larger than that at N/P = 4 (approximately 120 nm), with the smallest size observed at N/P = 6 (approximately 90 nm). These results indicate that a higher N/P ratio can effectively modulate and reduce the particle size of LNPs.

**Table 1.** Physicochemical Properties of LNPs Prepared with Different N/P Ratios.

|         | Size (nm) | Zeta (mV) | PDI    | EE%   |
|---------|-----------|-----------|--------|-------|
| N/P = 2 | 143.2     | 6.035     | 0.116  | 75.4% |
| N/P = 4 | 126.6     | 7.585     | 0.1539 | 92.0% |
| N/P = 6 | 90.55     | 25.18     | 0.1729 | 99.5% |

Based on encapsulation efficiency, mechanistic insights, and separation analysis, significant differences in encapsulation efficiency were observed among LNPs prepared with different N/P ratios: N/P = 6 showed the highest efficiency, up to 99.5%, followed by N/P = 4, while N/P = 2 performed relatively poorly, only 75.4% (Figure 1A). Mechanistically, a higher N/P ratio increases the proportion of cationic lipid to nucleic acid, thereby elevating the net positive charge [21]. However, the overall physicochemical properties of LNPs across different formulations did not exhibit marked differences, which may obscure critical variations between formulations. To address this, S-DGC was employed to separate LNPs and analyze their density distribution profiles. S-DGC separation revealed that for all three N/P ratios (2, 4, and 6), a portion of the LNP components was distributed in the top 0% sucrose density layer (Figure 1C). Combined with agarose gel electrophoresis results (Figure 1B), it was observed that most components of N/P = 6 LNPs were uniformly distributed within the 0–20% sucrose density range. LNPs with N/P = 2 and 4 exhibited similar distribution patterns. Within this density interval, the particle size and zeta poten-

tial of the separated fractions remained stable across all three formulations, with N/P = 2 and 4 showing relatively low polydispersity index (PDI) values, with most values below 0.15, indicating more uniform particle size distributions. The three formulations exhibited a significant increase in particle size exceeding 300 nm within the 30% sucrose density layer (commencing around the 20th sample), accompanied by a marked decrease in zeta potential, which became negative (Figure 1D,E,H).



**Figure 1.** Characterization of LNPs with N/P ratios of 2, 4, and 6 before and after S-DGC separation. (A) Agarose gel electrophoresis of pre-separation LNP samples (N/P = 2, 4, 6). (B) Agarose gel electrophoresis of fractions collected after S-DGC separation of LNPs (N/P = 6). (C) Schematic diagram of S-DGC separation profiles for LNPs with N/P = 2, 4, and 6. (D) Particle size distribution of fractions obtained after S-DGC separation for each N/P ratio. (E) Zeta potential distribution of fractions obtained after S-DGC separation for each N/P ratio. (F) Reporter gene expression of pre-separation LNP samples (N/P = 2, 4, 6) under Fed (complete medium) conditions. (G) Transfection efficiency of pre-separation LNPs and post-S-DGC fractions from different density layers. (H) Polydispersity index (PDI) distribution of fractions obtained after S-DGC separation for each N/P ratio. Data are presented as mean  $\pm$  standard deviation (SD) from three independent experiments. Statistical significance was determined by a *t*-test compared with the control group (N/P = 2). \*\*\*\*  $p < 0.0001$ , ns: not significant.

To further clarify the functional performance of LNPs with different N/P ratios, the transfection activity of each formulation was systematically evaluated before and after S-DGC separation (Figure 1F,G). Prior to separation, LNPs with N/P = 2 and 4 exhibited significantly higher reporter gene expression than those with N/P = 6. After S-DGC separation, plasmid DNA-containing fractions from all three N/P groups showed detectable reporter expression under fed (complete medium) conditions. Specifically, formulations N/P = 2 and N/P = 4 demonstrated particularly outstanding transfection efficiency in the sucrose density range of 0% to 20%, achieving rates exceeding 70, comparable to pre-

separation transfection efficiency. In contrast, almost no expression was observed under serum-starved (–FBS) conditions. In summary, this study successfully applied S-DGC to characterize and visualize the heterogeneity of LNPs prepared with different N/P ratios. The results demonstrate that LNPs with N/P = 2, 4, and 6 can all form homogeneous and stable systems. Although lower N/P formulations (N/P = 2 and 4) exhibited higher transfection activity, they were associated with lower encapsulation efficiency and potential stability limitations compared to the higher N/P formulation.

## 2.2. Effects of Variations in Lipid Composition on LNPs

The structural and physicochemical properties of LNPs are not determined by a single lipid component but by the integrated effect of the lipid combination. Based on the N/P = 6 formulation, we systematically investigated the specific effects of omitting individual lipid components on the structure and physicochemical properties of LNPs. As demonstrated by the overall physicochemical properties of the unseparated LNPs in Table 2, the absence of lipid components leads to an increase in particle size and a reduction in encapsulation efficiency. The most significant changes were observed in the N/P = 6–Chol–DSPC formulation (Figure 2A), which exhibited an encapsulation efficiency of only 13.7%. Helper lipids, such as DSPC and cholesterol, play crucial roles in LNP systems. Previous studies have confirmed that these lipids contribute to the formation of stable nucleic acid–lipid complexes at neutral pH, thereby ensuring efficient nucleic acid encapsulation [22].


**Table 2.** Physicochemical Properties of LNPs with Different Lipid Compositions.

|                   | Size (nm) | Zeta (mV) | PDI    | EE%   |
|-------------------|-----------|-----------|--------|-------|
| N/P = 6–Chol      | 99.4      | 22.88     | 0.1356 | 96.4% |
| N/P = 6–DSPC      | 118.1     | 7.421     | 0.148  | 98.5% |
| N/P = 6–Chol–DSPC | 119.8     | –15.2     | 0.1929 | 13.7% |

To further validate the impact of lipid omission on LNP homogeneity, each formulation was analyzed by S-DGC. The results showed that most components of the N/P = 6–Chol formulation were evenly distributed within the 0–10% density region. In contrast, the majority of components from the N/P = 6–DSPC and N/P = 6–Chol–DSPC formulations accumulated in the 0% density layer, with the latter exhibiting poorer distribution uniformity due to its lower encapsulation efficiency (Figure 2B,C). Furthermore, after S-DGC separation, the particle size (average ~160 nm) and zeta potential (average ~–5 mV) of the fractions from the N/P = 6–Chol–DSPC formulation showed no significant variation across fractions. However, compared to the N/P = 6–Chol and N/P = 6–DSPC formulations, this formulation displayed larger overall particle size, lower zeta potential, and a higher PDI, further confirming its broader size distribution and poorer dispersion homogeneity (Figure 2D,E,H). In vitro transfection results demonstrated that both the N/P = 6–Chol and N/P = 6–DSPC formulations exhibited weak reporter gene expression under fed (complete medium) conditions. The expression level of N/P = 6–DSPC was higher than that of N/P = 6–Chol, reaching over 40%, with the highest transfection efficiency observed in the fractions from the 10% and 20% density layers. In contrast, no reporter gene expression was detected in any fraction of the N/P = 6–Chol–DSPC formulation, either before or after S-DGC separation (Figure 2F,G).

These results demonstrate that S-DGC can effectively separate LNPs with different lipid omissions based on their density differences. Furthermore, they confirm the critical role of cholesterol and DSPC in maintaining the structural stability of LNPs during storage and intracellular trafficking. The absence of these helper lipids not only significantly

impairs the nucleic acid encapsulation capability of LNPs but also directly affects their intracellular transfection and reporter gene expression performance.



**Figure 2.** Characterization of LNPs with N/P = 6 lacking cholesterol (N/P = 6-Chol), DSPC (N/P = 6-DSPC), or both (N/P = 6-Chol-DSPC), before and after S-DGC separation. (A) Agarose gel electrophoresis of pre-separation LNP samples. (B) Agarose gel electrophoresis of fractions collected after S-DGC separation. (C) Schematic illustration of the S-DGC separation profiles. (D) Particle size distribution of the post-S-DGC fractions. (E) Zeta potential distribution of the post-S-DGC fractions. (F) Reporter gene expression of pre-separation LNP samples under fed (complete medium) conditions. (G) Transfection efficiency of pre-separation LNPs and post-S-DGC fractions from different density layers (shown for N/P = 6-Chol and N/P = 6-DSPC). (H) Polydispersity index (PDI) distribution of the post-S-DGC fractions. Data are presented as mean  $\pm$  standard deviation (SD) from three independent experiments. Statistical significance was determined by Student's *t*-test compared to the control group (N/P = 6-Chol). \*  $p < 0.05$ , \*\*\*  $p < 0.001$ , \*\*\*\*  $p < 0.0001$ ; ns, not significant.

### 2.3. Effect of Microfluidic Flow Rate on LNPs


Microfluidic mixing is currently the mainstream technique for the preparation of LNPs, with various devices having been developed for their scalable production. This technology enables laminar flow mixing by precisely controlling the flow rate ratio of the two fluid phases, thereby producing LNPs with high reproducibility and uniform size [23]. Accordingly, we employed microfluidic mixing to prepare DNA-loaded LNPs based on the standard formulation (N/P = 4), using five different total flow rates: 8, 10, 12, 15, and 18 mL/min. As shown in Table 3, the overall physicochemical properties of the prepared LNPs did not exhibit a clear trend across the tested flow rates. Therefore, S-DGC

was subsequently applied to further investigate the characteristics of LNP subpopulations separated by density.

**Table 3.** Physicochemical Properties of LNPs (Standard Formulation, N/P = 4) Prepared at Different Flow Rates.

|           | Size (nm) | Zeta (mV) | PDI    | EE%   |
|-----------|-----------|-----------|--------|-------|
| 8 mL/min  | 101.6     | 16.19     | 0.2075 | 92.2% |
| 10 mL/min | 91.81     | 18.06     | 0.2019 | 97.3% |
| 12 mL/min | 101.9     | 7.585     | 0.2117 | 99.3% |
| 15 mL/min | 94.78     | 13.43     | 0.2121 | 91.7% |
| 18 mL/min | 106.5     | 14.09     | 0.1903 | 94.2% |

S-DGC results indicated that LNPs prepared at different flow rates exhibited density distribution profiles similar to that shown in Figure 1C after separation: only a small fraction of LNP components remained at the top of the gradient, while the majority were uniformly distributed within the 0–20% sucrose layers, all of which are less than 200 nm (fractions 1–19). Within this region, both the zeta potential and particle size of the separated fractions remained stable (Figure 3A,B). In contrast, within the 30% sucrose layer, LNPs from all flow rates showed marked physicochemical abnormalities: a sharp drop in zeta potential accompanied by a pronounced increase in particle size and PDI (Figure 3A–C).



**Figure 3.** Characterization of fractions from LNPs (N/P = 4) prepared at different flow rates after S-DGC separation. (A) Particle size distribution of the post-S-DGC fractions. (The discontinuous design of the axes marked with double diagonal lines in the figure is due to the large data range). (B) Zeta potential distribution of the post-S-DGC fractions. (C) Polydispersity index (PDI) distribution of the post-S-DGC fractions. (D) Transfection efficiency of LNPs before and after S-DGC separation.

Transfection of HeLa cells with LNPs collected before and after S-DGC separation revealed that LNPs prepared at a flow rate of 12 mL/min yielded significantly higher

reporter gene expression than those prepared at other flow rates (Figure 3D). In summary, S-DGC analysis demonstrated that LNPs prepared at flow rates of 8, 10, 12, 15, and 18 mL/min showed no clear differences in their overall physicochemical properties and could all form homogeneous systems, which supports the robustness of the microfluidic preparation process. However, this does not rule out the possibility of subtle structural variations among the formulations.


#### 2.4. Impact of Varying PEG-Lipid Concentrations on LNPs

Polyethylene glycol (PEG) is a hydrophilic polymer widely used in the preparation and storage of LNPs. PEG-lipids stabilize the structure by providing a steric barrier that both drives self-assembly and prevents particle aggregation [24]. In this study, LNPs based on the standard N/P = 4 formulation were prepared using microfluidic mixing at a fixed total flow rate of 12 mL/min, with PEG-lipid concentrations set at 0.5%, 1.5%, and 2.5% to evaluate their influence on the physicochemical properties of LNPs. Table 4 presents the overall physicochemical properties results, demonstrating that the particle size of LNPs exhibits a significant decreasing trend with increasing PEG proportion. At a PEG concentration of 0.5%, the particle size reached 202 nm, whereas at 2.5% concentration, it decreased to 118.7 nm. Concurrently, the polydispersity index (PDI) progressively increased, indicating that the PEG-to-lipid ratio significantly influences the structure and physicochemical properties of LNPs.

**Table 4.** Physicochemical Characterization of LNPs (N/P = 4) at Varying PEG-Lipid Concentrations.

| PEG (%) | Size (nm) | Zeta (mV) | PDI    | EE%   |
|---------|-----------|-----------|--------|-------|
| 0.5     | 202       | 16.38     | 0.2028 | 96.6% |
| 1.5     | 142       | 17.46     | 0.2641 | 97.9% |
| 2.5     | 118.7     | 14.84     | 0.3222 | 99.3% |

Figure 4A shows the agarose gel electrophoresis of LNPs before S-DGC separation, indicating satisfactory encapsulation for all three formulations with different PEG-lipid concentrations. The primary role of PEG-lipids is to prevent particle aggregation. At a low PEG concentration (0.5%), insufficient surface coverage during LNP formation leads to particle fusion, resulting in larger particle sizes. After density-based separation by S-DGC, the distribution profiles (Figure 4C) and the corresponding characterizations of particle size, zeta potential, and PDI for each fraction (Figure 4D–F) revealed that LNPs with 1.5% and 2.5% PEG were uniformly distributed within the 0–20% density layers. In contrast, within the high-density 30% sucrose layer (starting around fraction 20), a significant increase in particle size and a sharp decrease in zeta potential were observed. From an overall trend perspective, the majority of components in the PEG 0.5% formulation LNPs are distributed in the upper layer of the gradient column. Most particles exhibit diameters exceeding 200 nm, with a decreasing trend in zeta potential and poor stability. Their PDI shows a gradual increase from the low-density layer to the high-density layer. Post-separation agarose gel electrophoresis (Figure 4B) further confirmed that at 0.5% PEG, considerable nucleic acid accumulation occurred in the 0% density layer, and compared with the lysed sample, some nucleic acid remained unencapsulated in the intact LNPs. To more directly visualize the density distribution, the absorbance of pre-separation samples and fractions 1, 5, 10, and 19 was measured using a full-wavelength scan on a microplate reader. Absorbance at 360 nm (Figure 4G) showed that lipid components of the 0.5% PEG formulation accumulated mainly in the upper gradient, whereas the 1.5% and 2.5% PEG formulations were evenly distributed within the 0–20% density layers and exhibited better encapsulation.



**Figure 4.** Characterization of LNPs (N/P = 4) with different PEG-lipid concentrations before and after S-DGC separation. (A) Agarose gel electrophoresis of pre-separation LNP samples containing 0.5%, 1.5%, or 2.5% PEG-lipid. (B) Agarose gel electrophoresis of fractions collected after S-DGC separation of LNPs with 0.5% PEG-lipid. (C) Schematic illustration of S-DGC separation profiles for LNPs with 0.5%, 1.5%, and 2.5% PEG-lipid. (D) Particle size distribution of the post-S-DGC fractions. (The discontinuous design of the axes marked with double diagonal lines in the figure is due to the large data range.) (E) Zeta-potential distribution of the post-S-DGC fractions. (F) Polydispersity index (PDI) distribution of the post-S-DGC fractions. (G) Absorbance at 360 nm ( $OD_{360}$ ) of pre-separation samples and selected post-S-DGC fractions (1, 5, 10, and 19). Asterisks indicate significant differences compared to the 0.5% PEG group ( $n = 3$ ). (H) Reporter gene expression of pre-separation LNPs under fed (complete medium) conditions. (I) Transfection efficiency of pre-separation LNPs and post-S-DGC fractions from different density layers. Data are presented as mean  $\pm$  standard deviation (SD) from three independent experiments. Statistical significance was determined by Student's *t*-test relative to the control group (1.5% PEG). \*\*\*  $p < 0.001$ , \*\*\*\*  $p < 0.0001$ ; ns, not significant.

Previous studies have shown that PEG influences the circulation time and cellular interactions of LNPs, with its content significantly affecting in vitro transfection [25]. Therefore, we transfected HeLa cells with LNPs (before and after S-DGC separation) containing different PEG concentrations. The results (Figure 4H,I) showed that DNA-containing

fractions from all three PEG formulations, both before and after separation, mediated high transfection efficiency under fed (complete medium) conditions, with the 1.5% PEG formulation performing the best, reaching approximately 70%. Combined with the S-DGC separation data, these findings indicate that at PEG concentrations of 1.5% and above, more stable and compact LNPs are formed. These LNPs are uniformly distributed in the 0–20% density layers after S-DGC, reflecting significantly improved homogeneity of density-based subpopulations. Although the overall PDI increased slightly, the consistency of the core functional subpopulation was enhanced, thereby contributing to superior transfection efficiency.

## 2.5. Freeze–Thaw Stability Evaluation

The field of mRNA vaccine development is advancing rapidly; however, the inherent instability of mRNA molecules and the physical stability challenges of mRNA formulations based on LNPs—such as particle aggregation, fusion, and nucleic acid leakage—remain significant concerns. Commercially available mRNA-LNP products still require frozen storage and transportation to maintain their biological activity, underscoring the importance of systematic stability evaluation for the industrial translation of LNP-based therapeutics [26,27]. In this study, the freeze–thaw stability of a standard LNP formulation (N/P = 4) was evaluated. The experiment included three sample groups: Group A was stored at 4 °C for one week, while Groups B and C underwent three freeze–thaw cycles to simulate potential temperature fluctuations during cold-chain transportation. The physicochemical property test results in Tables 5 and 6 indicate that after one week of storage, the LNP samples in the 4 °C storage group (Group A) and the −80 °C freeze–thaw group with cryoprotectant (Group C) maintained particle sizes below 200 nm with virtually unchanged zeta potentials. In contrast, the freeze–thaw group without cryoprotectant (Group B) exhibited significant alterations: particle size increased to 1323 nm, zeta potential decreased to 2.633 mV and encapsulation efficiency decreased to merely 5.3%. This indicates structural disruption of the LNPs in this group, leading to leakage of the encapsulated nucleic acids.


**Table 5.** Physicochemical Properties of Different Groups of LNPs (N/P = 4) before Freeze–Thaw.

| Before                  | Size (nm) | Zeta (mV) | PDI    | EE%   |
|-------------------------|-----------|-----------|--------|-------|
| (A) 4 °C                | 137.3     | 16.16     | 0.2066 | 96.2% |
| (B) −80 °C              | 126.8     | 16.91     | 0.1712 | 98.5% |
| (C) −80 °C + 5% sucrose | 148.1     | 14.57     | 0.1581 | 98.9% |

**Table 6.** Physicochemical Properties of Different Groups of LNPs (N/P = 4) after Freeze–Thaw.

| After                   | Size (nm) | Zeta (mV) | PDI    | EE%   |
|-------------------------|-----------|-----------|--------|-------|
| (A) 4 °C                | 180.5     | 15.86     | 0.3571 | 91.7% |
| (B) −80 °C              | 1323      | 2.633     | 0.5743 | 5.3%  |
| (C) −80 °C + 5% sucrose | 161.2     | 13.7      | 0.1408 | 96.3% |

After freeze–thaw treatment, LNPs in Group B exhibited clear signs of stability deterioration: the sample appeared as a turbid milky-white suspension with visible precipitate at the bottom of the centrifuge tube. Agarose gel electrophoresis further revealed that most of the encapsulated nucleic acid had been released (Figure 5A). In contrast, samples stored at 4 °C (Group A) showed no significant changes in appearance or physicochemical state compared to their condition 7 days earlier, indicating good stability under this storage condition.



**Figure 5.** Characterization of LNPs (N/P = 4) from freeze–thaw stability studies before and after S-DGC separation. **(A)** Agarose gel electrophoresis of pre-separation LNP samples after different storage/freeze–thaw treatments: storage at 4 °C (Group A), freeze–thaw at –80 °C without cryoprotectant (Group B), and freeze–thaw at –80 °C with cryoprotectant (Group C). **(B)** Agarose gel electrophoresis of fractions collected after S-DGC separation of the three groups. **(C)** Schematic diagram of the S-DGC separation profiles for the three groups. **(D)** Particle size distribution of the post-S-DGC fractions. **(E)** Zeta-potential distribution of the post-S-DGC fractions. **(F)** Transfection efficiency of LNPs without freeze–thaw (NF) and after freeze–thaw, both before (“Before”) and after S-DGC separation for the three groups.

To further investigate the impact of freeze–thaw cycling on LNP structural integrity, all groups were analyzed by S-DGC. The results showed that samples from the 4 °C storage group (Group A) were uniformly distributed within the 0–20% density layers. Samples from the –80 °C freeze–thaw group with cryoprotectants (Group C) still displayed partial distribution in the 0–20% density range, suggesting that a portion of the LNPs remained homogeneous and stable. However, samples from the –80 °C freeze–thaw group without cryoprotectants (Group B) exhibited an abnormal distribution pattern: some components accumulated in the upper layers, and particle aggregation was observed around the 20–30% density interface (Figure 5B,C). Characterization of particle size and zeta potential for the post-S-DGC fractions indicated that both the 4 °C storage group (Group A) and the –80 °C freeze–thaw group with cryoprotectants (Group C) maintained uniform size and zeta potential distributions within the 0–20% density region. In contrast, fractions from the –80 °C freeze–thaw group without cryoprotectants (Group B) showed significantly increased particle size and decreased zeta potential after treatment (Figure 5D,E). Results from cell transfection experiments demonstrated that following S-DGC separation, the transfection efficiency of components within the 0–20% density range exhibited no significant difference compared to pre-freezing and pre-separation samples in both the 4 °C storage group (Group A) and the –80 °C freeze–thaw + cryoprotectant group (Group C).

These samples maintained high transfection activity at 60–80% (Figure 5F). In contrast, for the  $-80^{\circ}\text{C}$  freeze–thaw group without cryoprotectants (Group B), only samples collected near the 20–30% density interface after freeze–thaw cycling exhibited about 30% transfection efficiency. In summary, combining freeze–thaw testing with S-DGC separation and subsequent characterization revealed that the addition of cryoprotectants effectively prevents structural damage to LNPs during freeze–thaw cycles. In the absence of cryoprotectants, freeze–thaw treatment leads to looser LNP structures, particle aggregation, leakage of initially encapsulated nucleic acid, an increase in particle density, and a consequent significant reduction in transfection function.

### 3. Discussion

LNPs are pivotal carriers in nucleic acid delivery, and their functional stability and structural homogeneity are crucial determinants of clinical translation success. As noted by Yuan et al. [28], the physicochemical properties of LNPs—including size, surface hydrophobicity, surface charge, surface modifications, and lipid composition—significantly influence their absorption, transport, distribution, clearance, and biological interactions. Heterogeneity in LNPs arises from multi-dimensional factors such as formulation composition and manufacturing processes, posing substantial challenges to product quality and batch consistency. Under current technologies, it remains difficult to produce LNPs with uniform physicochemical characteristics. Moreover, conventional analytical techniques often fail to resolve subtle internal differences in density, structure, and composition, thereby limiting a deeper understanding of the relationship between structure and function.

This study systematically investigated the effects of formulation variables—N/P ratio, lipid composition, and PEG-lipid concentration—as well as microfluidic processing parameters on LNP heterogeneity. S-DGC was employed to effectively separate and characterize LNP subpopulations. The results demonstrate that S-DGC is a powerful method for resolving LNP heterogeneity based on density differences, particularly useful for uncovering structural and functional variations that may be obscured by conventional size-based characterization.

First, the N/P ratio, a core parameter in LNP design, regulates heterogeneity primarily through the dynamic electrostatic balance between cationic lipids and nucleic acids. We found that increasing the N/P ratio significantly reduced particle size and improved encapsulation efficiency, which can be attributed to enhanced electrostatic interactions between the cationic lipids and the nucleic acids. A higher positive charge density strengthens electrostatic adsorption, promoting tighter lipid–nucleic acid complexation and facilitating the formation of smaller, more compact particles—a finding consistent with reports by Kim et al. on the role of cationic lipids in nucleic acid encapsulation [29,30]. Interestingly, despite its superior encapsulation, the high N/P ratio (N/P = 6) formulation exhibited lower transfection activity compared to those with N/P = 2 and 4. This may be because the moderate surface charge density at lower N/P ratios reduces electrostatic repulsion during cellular uptake, while their relatively looser structure may facilitate intracellular nucleic acid release. This indicates that ‘more’ electrostatic interactions do not invariably equate to ‘better’ functional output. In this regard, we propose that at N/P = 6, nucleic acids may be compressed excessively tightly within the lipid core. Whilst advantageous for storage, this may compromise the efficiency of nucleic acid dissociation and release following escape from the endosome. Furthermore, the extremely high surface positive charge may adversely affect intracellular transport pathways and ultimate escape efficiency by enhancing non-specific binding to serum proteins or excessive interaction with the endosomal membrane post-endocytosis. S-DGC separation results further demonstrate that distinct N/P ratio LNPs exhibit significantly different characteristics within their den-

sity subpopulations. Consequently, formulation optimization requires striking a balance between encapsulation efficiency and functional activity. Second, the modulation of LNP heterogeneity by lipid composition relies on the synergistic action of all components. The omission of helper lipids (cholesterol and DSPC) markedly compromised LNP structural integrity and functional performance. Our study confirmed that the absence of either DSPC or cholesterol led to increased particle size, reduced encapsulation efficiency, and, after S-DGC, predominant enrichment in low-density regions. This aligns with the conclusion by Kulkarni et al. that helper lipids are indispensable for maintaining bilayer integrity and promoting endosomal escape [22]. Their accumulation in low-density layers suggests a looser, less dense structure, likely due to disrupted lipid packing or failure to form a typical core-shell structure in the absence of cholesterol and DSPC, resulting in complexes with a density <1 g/mL. Notably, the formulation simultaneously lacking both DSPC and cholesterol (N/P = 6–Chol–DSPC) exhibited an encapsulation efficiency of only 13.7% and showed no detectable transfection signal. In contrast, complexes containing cholesterol and DSPC may form denser crystalline structures, causing migration to higher-density regions. These findings underscore the irreplaceable role of helper lipids in nucleic acid encapsulation and intracellular function. Therefore, LNP heterogeneity is not only reflected in inter-particle physicochemical differences but is also directly linked to the integrity of the lipid network. The absence of a single lipid component can trigger cascading effects, leading to overall functional deterioration of the population.

PEG-lipid, a key surface-modifying component, exerts a dose-dependent effect on LNP heterogeneity—a finding consistent with the work of Liu et al. on optimizing mRNA delivery efficiency through PEG content [31]. At a low concentration (0.5%), insufficient PEG surface coverage leads to inadequate steric hindrance, causing particle fusion during self-assembly. This results in larger, structurally loose low-density subpopulations with substantial amounts of unencapsulated nucleic acid, ultimately increasing overall heterogeneity. In contrast, when the PEG concentration was increased to 1.5% or higher, a dense surface barrier formed, effectively preventing aggregation. This yielded LNPs uniformly distributed in the 0–20% density layers, forming a compact, transfection-efficient dominant subpopulation. However, while a high PEG concentration (2.5%) maintained population homogeneity, it also led to a slight increase in the PDI, potentially due to excessive PEGylation causing an imbalance in steric repulsion. Thus, optimizing PEG concentration requires balancing population homogeneity with structural stability.

Freeze–thaw stability studies revealed how environmental stress can induce heterogeneity. LNPs can be unstable during freeze–thaw cycles, with potential changes in morphology and encapsulation efficiency at suboptimal temperatures. Components such as phospholipids and ionizable lipids are susceptible to temperature- and pH-dependent hydrolysis, and impurities in PEG-lipids may promote oxidation of cholesterol [26]. Our results showed that LNPs without cryoprotectants underwent particle aggregation, nucleic acid leakage, and a shift toward higher density regions in S-DGC after freeze–thaw, visually demonstrating their physical instability. The addition of sucrose as a cryoprotectant effectively preserved LNP integrity and function, corroborating findings by Ayat et al. that sucrose enhances the freeze–thaw stability of mRNA vaccines [32]. This outcome not only provides technical guidance for the cold-chain storage and transport of LNPs but also demonstrates that S-DGC can visually capture heterogeneity changes induced by stability stress, offering a novel, visual tool for formulation stability assessment.

Furthermore, the robustness of the microfluidic process is essential for the scalable production of homogeneous LNPs. In this study, LNPs prepared at different flow rates (8–18 mL/min) showed no significant differences in overall physicochemical properties, confirming the reliability of the process. However, S-DGC separation revealed highly simi-

lar density subpopulation distributions and physicochemical profiles across all flow rate groups, failing to clearly delineate subtle effects of flow rate on internal LNP structure. This suggests a limitation of the method in resolving micro-heterogeneity induced by process parameters, possibly due to the resolution limit of S-DGC. The impact of microfluidic flow rate might manifest at the micro-level—such as in internal lipid packing or nucleic acid encapsulation patterns—rather than as macroscopic density differences. Therefore, a single characterization technique is insufficient for a comprehensive analysis of LNP heterogeneity. Future research on high-efficiency subpopulations should employ higher-resolution techniques such as cryo-electron microscopy (Cryo-EM) or analytical ultracentrifugation (AUC) for finer structural analysis. In vivo validation of different density subpopulations is also necessary, along with careful consideration of “ineffective subpopulations” (e.g., empty LNPs) generated by certain formulations or processes, to deeply investigate the regulatory mechanisms of process parameters on LNP fine structure.

While this study confirms the effectiveness of S-DGC in resolving LNP heterogeneity, it also reveals its limitations: the inability to distinguish subpopulations with similar sizes but different internal structures or compositions, limited sensitivity to process parameters like flow rate, and the lack of direct characterization of lipid composition and nucleic acid encapsulation patterns within different density fractions. Future work should integrate multiple orthogonal analytical techniques (e.g., analytical ultracentrifugation, cryo-electron microscopy, mass spectrometry) to achieve a more comprehensive analysis of LNP heterogeneity. In vivo experiments should also be conducted to validate differences in the biodistribution, therapeutic efficacy, and safety profiles of dominant subpopulations, thereby providing a more robust theoretical foundation for the targeted optimization of LNPs.

## 4. Materials and Methods

### 4.1. Plasmid Extraction

The GFP-encoding plasmid was transformed into *E. coli* DH5 $\alpha$  competent cells using a standard heat-shock protocol. Subsequently, the transformed cells were inoculated into liquid LB medium supplemented with 0.1% kanamycin and cultured overnight (12–16 h) at 37 °C with shaking at 250 rpm. Plasmid DNA was then extracted using a commercial endotoxin-free maxiprep kit (TIANGEN, Beijing, China) according to the manufacturer’s instructions.

### 4.2. Preparation and Characterization of DNA-LNPs

DNA-loaded LNPs were prepared using a clinically relevant LNP formulation (denoted as the “standard formulation”) composed of the ionizable cationic lipid SM-102, DSPC, cholesterol, and DMG-PEG 2000 at a molar ratio of 50:10:38.5:1.5. The lipid mixture was dissolved in anhydrous ethanol to form the organic phase. The nucleic acid was diluted in 20 mM sodium citrate buffer (pH 4.0) to prepare the aqueous phase. The two phases were mixed at a volume ratio of 3:1 (aqueous: organic) using a microfluidic chip. The resulting nanoparticles were subsequently dialyzed for 2–3 h at 4 °C against a dialysis buffer (pH 7.8) using 10 kDa MWCO dialysis tubing (16 mm width). Particle size and zeta potential of the DNA-LNPs before and after dialysis were measured using a Malvern Zetasizer Pro laser diffraction analyzer (Malvern Panalytical Ltd., Malvern, United Kingdom). Encapsulation efficiency was assessed by agarose gel electrophoresis. For each sample, two aliquots equivalent to 500 ng of theoretical nucleic acid content were prepared. One aliquot was treated with 1% Triton X-100 and incubated at 37 °C for 10 min to disrupt the LNPs and release the nucleic acid, allowing evaluation of nucleic acid integrity within the complexes.

#### 4.3. Sucrose Gradient Density Centrifugation (S-DGC)

Prepare sucrose solutions of 0%, 10%, 20%, and 30% concentrations using ultrapure water, with densities of 0.998 g/mL, 1.038 g/mL, 1.081 g/mL, and 1.127 g/mL, respectively (sterilized by filtration through a 0.22 µm microporous membrane). Discontinuous sucrose density gradient columns (approximately 0–30% *w/v* sucrose) were prepared by sequentially layering 2 mL of each sucrose solution into centrifuge tubes in order of decreasing concentration (i.e., 30%, 20%, 10%, and 0% from bottom to top). The prepared gradient columns were stored at −80 °C until use. Prior to separation, the gradient columns were thawed at 4 °C. DNA-LNP samples were carefully loaded onto the top of the gradient. The loaded columns were placed in a rotor and centrifuged at 110,000× *g* for 16 h at 13–16 °C using an Avanti JXN-30 floor-type ultracentrifuge (BECKMAN COULTER, Shanghai, China). After centrifugation, fractions of approximately 450–500 µL were collected sequentially from the top of the gradient using a micropipette, and each fraction was subsequently characterized.

#### 4.4. Cell Transfection

HeLa cells were cultured in complete medium, consisting of high-glucose DMEM supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin, at 37 °C under 5% CO<sub>2</sub>. When cells reached approximately 80% confluence, they were seeded in 24-well plates at a density of  $8 \times 10^4$  cells per well and allowed to adhere for at least 6 h prior to transfection. Once cell attachment was confirmed and confluence reached 70–90%, the cultures were divided into two groups: one subjected to serum starvation for 2 h (−FBS) and the other maintained in complete medium (Fed). Following the respective treatments, cells were transfected with DNA-LNPs corresponding to 2 µg of GFP plasmid per well and incubated overnight. The medium was then replaced with fresh complete medium, and live cell nuclei were stained with 10 µg/mL Hoechst 33342 (Thermo Fisher Scientific, Meridian Rd. Rockford, IL, USA) for 30 min. Images were acquired using a high-content imaging system, and transfection efficiency was quantified with ImageJ 1.8.0 software.

#### 4.5. Statistical Analysis

Statistical analysis was performed using GraphPad Prism 8. All values are presented as mean ± standard deviation (SD) from at least three independent experiments. Comparisons between groups were conducted using two-way analysis of variance (ANOVA). Differences were considered statistically significant at  $p < 0.05$ , and highly significant at  $p < 0.01$ . In this study, two-way analysis of variance (ANOVA) was primarily employed to compare differences in specific physicochemical or functional parameters between various LNP formulations across different density layers (i.e., distinct collected fractions) following separation via S-DGC. Consequently, the two factors typically incorporated into the analysis were: formulation factor and density layer/separated fraction factor.

### 5. Conclusions

Through a comprehensive analysis combining agarose gel electrophoresis, particle size and zeta potential characterization, and cell transfection assays, this study demonstrates that S-DGC is an effective method for resolving the heterogeneity of LNPs under varying N/P ratios, lipid compositions, and PEG-lipid concentrations. Significant differences in physicochemical properties and \*in vitro\* transfection activity were observed among the separated density-based subpopulations. However, the technique showed a clear limitation: it could not resolve the subtle differences between LNPs prepared at different microfluidic flow rates within the tested range.

The experimental results indicate that an increased N/P ratio helps reduce particle size and improve encapsulation efficiency, yet requires balanced optimization with transfection activity. Helper lipids (cholesterol and DSPC) are essential for maintaining LNP structural integrity and functional performance. A PEG-lipid concentration of 1.5% or higher significantly enhances LNP homogeneity, stability, and transfection efficiency, whereas a low PEG concentration (0.5%) promotes particle fusion and functional decline. Freeze–thaw stress can cause irreversible structural damage to LNPs, leading to particle aggregation, nucleic acid leakage, and characteristic distribution patterns in S-DGC, where particles migrate towards the higher-density middle and lower layers. The addition of cryoprotectants (such as sucrose) effectively maintains their stability and functionality. Therefore, when cryopreserving LNPs, it is essential to incorporate cryoprotectants. The microfluidic preparation process demonstrated good robustness across flow rates of 8–18 mL/min, though S-DGC exhibited limited resolution in detecting flow-rate-induced microstructural variations. In summary, this work provides an important methodological foundation for the rational design, process optimization, and stability assessment of LNPs. It underscores the necessity of holistically considering formulation composition, process parameters, and storage conditions during pharmaceutical development to advance the translation of LNPs toward more efficient and stable clinical applications.

**Author Contributions:** Y.H. and G.Z. performed experiments and wrote the draft manuscript. B.P. conceived the study and reviewed the manuscript. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** The original contributions presented in this study are included in the article. Further inquiries can be directed to the corresponding author.

**Conflicts of Interest:** The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

## References

1. Hou, X.; Zaks, T.; Langer, R.; Dong, Y. Lipid nanoparticles for mRNA delivery. *Nat. Rev. Mater.* **2021**, *6*, 1078–1094. [[CrossRef](#)] [[PubMed](#)]
2. Wang, B.; Shen, B.; Xiang, W.; Shen, H. Advances in the study of LNPs for mRNA delivery and clinical applications. *Virus Genes* **2024**, *60*, 577–591. [[CrossRef](#)] [[PubMed](#)]
3. Zhou, Y.; Ge, Q.; Wang, X.; Wang, Y.; Sun, Q.; Wang, J.; Yang, T.; Wang, C. Advances in Lipid Nanoparticle-Based Disease Treatment. *ChemMedChem* **2025**, *20*, e202400938. [[CrossRef](#)] [[PubMed](#)]
4. Kon, E.; Ad-El, N.; Hazan-Halevy, I.; Stotsky-Oterin, L.; Peer, D. Targeting cancer with mRNA–lipid nanoparticles: Key considerations and future prospects. *Nat. Rev. Clin. Oncol.* **2023**, *20*, 739–754. [[CrossRef](#)]
5. Chen, Y.; Zhang, C.; Huang, Y.; Ma, Y.; Song, Q.; Chen, H.; Jiang, G.; Gao, X. Intranasal drug delivery: The interaction between nanoparticles and the nose-to-brain pathway. *Adv. Drug Deliv. Rev.* **2024**, *207*, 115196. [[CrossRef](#)]
6. Shahzad, A.; Teng, Z.; Yameen, M.; Liu, W.; Cui, K.; Liu, X.; Sun, Y.; Duan, Q.; Xia, J.; Dong, Y.; et al. Innovative lipid nanoparticles: A cutting-edge approach for potential renal cell carcinoma therapeutics. *Biomed. Pharmacother.* **2024**, *180*, 117465. [[CrossRef](#)]
7. Jeong, M.; Lee, Y.; Park, J.; Jung, H.; Lee, H. Lipid nanoparticles (LNPs) for in vivo RNA delivery and their breakthrough technology for future applications. *Adv. Drug Deliv. Rev.* **2023**, *200*, 114990. [[CrossRef](#)]
8. Zong, Y.; Lin, Y.; Wei, T.; Cheng, Q. Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy. *Adv. Mater.* **2023**, *35*, e2303261. [[CrossRef](#)]

9. Albertsen, C.H.; Kulkarni, J.A.; Witzigmann, D.; Lind, M.; Petersson, K.; Simonsen, J.B. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. *Adv. Drug Deliv. Rev.* **2022**, *188*, 114416. [\[CrossRef\]](#)
10. Thanki, K.; Papai, S.; Lokras, A.; Rose, F.; Falkenberg, E.; Franzyk, H.; Foged, C. Application of a Quality-By-Design Approach to Optimise Lipid-Polymer Hybrid Nanoparticles Loaded with a Splice-Correction Antisense Oligonucleotide: Maximising Loading and Intracellular Delivery. *Pharm. Res.* **2019**, *36*, 37. [\[CrossRef\]](#)
11. Mendonca, M.C.; Kont, A.; Kowalski, P.S.; O'Driscoll, C.M. Design of lipid-based nanoparticles for delivery of therapeutic nucleic acids. *Drug Discov. Today* **2023**, *28*, 103505. [\[CrossRef\]](#) [\[PubMed\]](#)
12. Catenacci, L.; Rossi, R.; Sechi, F.; Buonocore, D.; Sorrenti, M.; Perteghella, S.; Peviani, M.; Bonferoni, M.C. Effect of Lipid Nanoparticle Physico-Chemical Properties and Composition on Their Interaction with the Immune System. *Pharmaceutics* **2024**, *16*, 1521. [\[CrossRef\]](#) [\[PubMed\]](#)
13. Zhang, J.; Pei, Y.; Zhang, H.; Wang, L.; Arrington, L.; Zhang, Y.; Glass, A.; Leone, A.M. Assessing the Heterogeneity Level in Lipid Nanoparticles for siRNA Delivery: Size-Based Separation, Compositional Heterogeneity, and Impact on Bioperformance. *Mol. Pharm.* **2012**, *10*, 397–405. [\[CrossRef\]](#) [\[PubMed\]](#)
14. Li, S.; Hu, Y.; Lin, J.; Schneiderman, Z.; Shao, F.; Wei, L.; Li, A.; Hsieh, K.; Kokkoli, E.; Curk, T.; et al. Single-Particle Spectroscopic Chromatography Reveals Heterogeneous RNA Loading and Size Correlations in Lipid Nanoparticles. *ACS Nano* **2024**, *18*, 15729–15743. [\[CrossRef\]](#)
15. Jerri, H.A.; Sheehan, W.P.; Snyder, C.E.; Velegol, D. Prolonging Density Gradient Stability. *Langmuir* **2009**, *26*, 4725–4731. [\[CrossRef\]](#)
16. Vaidya, A.; Parande, D.; Khadse, N.; Vargas-Montoya, N.; Agarwal, V.; Ortiz, C.; Ellis, G.; Kaushal, N.; Sarode, A.; Karve, S.; et al. Analytical Characterization of Heterogeneities in mRNA-Lipid Nanoparticles Using Sucrose Density Gradient Ultracentrifugation. *Anal. Chem.* **2024**, *96*, 5570–5579. [\[CrossRef\]](#)
17. Liao, S.; Wang, S.; Wadhwa, A.; Birkenshaw, A.; Fox, K.; Cheng, M.H.Y.; Casmil, I.C.; Magana, A.A.; Bathula, N.V.; Ho, C.H.; et al. Transfection Potency of Lipid Nanoparticles Containing mRNA Depends on Relative Loading Levels. *ACS Appl. Mater. Interfaces* **2024**, *17*, 3097–3105. [\[CrossRef\]](#)
18. Sakers, S.H.; Fiduccia, G.; Byrne, K.E.; Reddy, B.P.K.; Dahlman, J.E.; Prausnitz, M.R. The effect of mRNA-lipid nanoparticle composition on stability during microneedle patch manufacturing. *Eur. J. Pharm. Biopharm.* **2025**, *215*, 114819. [\[CrossRef\]](#)
19. Tang, X.; Zhang, Y.; Han, X. Ionizable Lipid Nanoparticles for mRNA Delivery. *Adv. NanoBiomed Res.* **2023**, *3*, 2300006. [\[CrossRef\]](#)
20. Borah, A.; Giacobbo, V.; Binici, B.; Baillie, R.; Perrie, Y. From in vitro to in vivo: The Dominant role of PEG-Lipids in LNP performance. *Eur. J. Pharm. Biopharm.* **2025**, *212*, 114726. [\[CrossRef\]](#)
21. Gary, D.J.; Min, J.; Kim, Y.; Park, K.; Won, Y.Y. The Effect of N/P Ratio on the In Vitro and In Vivo Interaction Properties of PEGylated Poly [2-(dimethylamino)ethyl methacrylate]-Based siRNA Complexes. *Macromol. Biosci.* **2013**, *13*, 1059–1071. [\[CrossRef\]](#) [\[PubMed\]](#)
22. Kulkarni, J.A.; Witzigmann, D.; Leung, J.; Tam, Y.Y.C.; Cullis, P.R. On the role of helper lipids in lipid nanoparticle formulations of siRNA. *Nanoscale* **2019**, *11*, 21733–21739. [\[CrossRef\]](#) [\[PubMed\]](#)
23. Maeki, M.; Uno, S.; Niwa, A.; Okada, Y.; Tokeshi, M. Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery. *J. Control. Release* **2022**, *344*, 80–96. [\[CrossRef\]](#) [\[PubMed\]](#)
24. Suzuki, T.; Suzuki, Y.; Hihara, T.; Kubara, K.; Kondo, K.; Hyodo, K.; Yamazaki, K.; Ishida, T.; Ishihara, H. PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: Faster PEG shedding attenuates anti-PEG IgM production. *Int. J. Pharm.* **2020**, *588*, 119792. [\[CrossRef\]](#)
25. Liu, W.; Zhang, M.; Lv, H.; Yang, C. Formulation-Driven Optimization of PEG-Lipid Content in Lipid Nanoparticles for Enhanced mRNA Delivery In Vitro and In Vivo. *Pharmaceutics* **2025**, *17*, 950. [\[CrossRef\]](#)
26. Uddin, M.N.; Roni, M.A. Challenges of Storage and Stability of mRNA-Based COVID-19 Vaccines. *Vaccines* **2021**, *9*, 1033. [\[CrossRef\]](#)
27. Schoenmaker, L.; Witzigmann, D.; Kulkarni, J.A.; Verbeke, R.; Kersten, G.; Jiskoot, W.; Crommelin, D.J. mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. *Int. J. Pharm.* **2021**, *601*, 120586. [\[CrossRef\]](#)
28. Yuan, Z.; Yan, R.; Fu, Z.; Wu, T.; Ren, C. Impact of physicochemical properties on biological effects of lipid nanoparticles: Are they completely safe. *Sci. Total. Environ.* **2024**, *927*, 172240. [\[CrossRef\]](#)
29. Kim, Y.; Park, J.; Choi, J.; Kim, M.; Seo, G.; Kim, J.; Park, J.A.; Lim, K.S.; Ha, S.J.; Kim, H.O. Physiological Barriers to Nucleic Acid Therapeutics and Engineering Strategies for Lipid Nanoparticle Design, Optimization, and Clinical Translation. *Pharmaceutics* **2025**, *17*, 1309. [\[CrossRef\]](#)
30. Aldosari, B.N.; Alfagih, I.M.; Almurshedi, A.S. Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines. *Pharmaceutics* **2021**, *13*, 206. [\[CrossRef\]](#)

31. Liu, L.; Kim, J.-H.; Li, Z.; Sun, M.; Northen, T.; Tang, J.; McIntosh, E.; Karve, S.S.; DeRosa, F. PEGylated lipid screening, composition optimization, and structure–activity relationship determination for lipid nanoparticle-mediated mRNA delivery. *Nanoscale* **2025**, *17*, 11329–11344. [[CrossRef](#)]
32. Ayat, N.R.; Sun, Z.; Sun, D.; Yin, M.; Hall, R.C.; Vaidya, A.M.; Liu, X.; Schilb, A.L.; Scheidt, J.H.; Lu, Z.R. Formulation of Biocompatible Targeted ECO/siRNA Nanoparticles with Long-Term Stability for Clinical Translation of RNAi. *Nucleic Acid Ther.* **2019**, *29*, 195–207. [[CrossRef](#)]

**Disclaimer/Publisher’s Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.